

Biorepository of A-bomb Survivors and their Offspring

Osamu Tanabe, M.D., Ph.D.

**Director of Biosample Research Center,
Radiation Effects Research Foundation (RERF)**

Outline

- **RERF Cohorts**
- **Biosample Research Center (BRC)**
- **Blood and Urine Samples**
- **DNA Extraction and QA/QC**
- **LIMS**
- **Pathological Samples**
- **Future Perspectives**

RERF Cohorts with Biosamples

A-bomb Survivors

Life Span Study (LSS)

120,000 [1950–]

Adult Health Study (AHS)

25,000 [1958–]

In Utero Study

3,600
[1945–]

(1,000)
[1978–]

Offspring of A-bomb Survivors

F1 Study

77,000 [1946–]

F1 Clinical Study (FOCS)


13,000 [2002–]

Trio Study

1,500 Trios [1985–]

Blood and Urine

RERF Cohorts with Biosamples



Storage Equipment at RERF

	Liquid N ₂ Tank	Upright –80°C Freezer	Robotic –80°C Freezer	–20°C Freezer	4°C Fridge
Hiroshima	33	42	1	2	1
Nagasaki	7	32	0	0	1
TOTAL	40	74	1	2	2

Liquid N₂ Tanks



Upright Freezers



**Robotic Freezer
Brooks BioStore II**



Biosample Research Center (BRC)

Established in 2013,


- To **centralize the management** of archived biosamples, and the **processing** of newly collected biosamples
- To ensure **secure preservation and quality control** of biosamples
- To **facilitate research use** of biosamples for both internal and external collaborative research

Biosample Research Center (BRC)

The BRC has been ...

- **Inventorying archived** blood and urine samples since 2014
- **Processing newly collected** blood and urine samples with new SOPs since 2015
- Storing both newly collected and archived samples in **Robotic Freezer** installed in 2016
- Establishing **SOPs for sample QA/QC**

Blood Processing Procedures



Samples from AHS and FOCS

Crude Sample	Volume	Processed Sample	Number of Tubes	
			AHS	FOCS
Urine	AHS/FOCS: 2 mL		4 (x 0.5 mL)	4 (x 0.5 mL)
Whole Blood	AHS/FOCS: 4 mL	Serum	~ 8 (x 0.2 mL)	~ 8 (x 0.2 mL)
		Blood Clot	1 (x 0.5 mL)	1 (x 0.5 mL)
EDTA-Blood	AHS: 3 mL FOCS: 2 mL	Plasma	~ 6 (x 0.2 mL)	~ 4 (x 0.2 mL)
		Red Blood Cells	1	1
		Granulocytes	1	1
		Mono-nuclear Cells	2	1
Heparin-Blood	AHS: 2 mL	Plasma	~ 4 (x 0.2 mL)	
		Red Blood Cells	1	
		Granulocytes	1	
		Mono-nuclear Cells	1	
TOTAL			~ 30	~ 20

Samples from AHS and FOCS

Crude Sample	Volume	Processed Sample	Number of Tubes	
			AHS	FOCS
Urine	AHS/FOCS: 2 mL	Urine	4 (x 0.5 mL)	4 (x 0.5 mL)
Whole Blood	AHS/FOCS: 4 mL	Serum	~ 8 (x 0.5 mL)	~ 8 (x 0.2 mL)
		Blood Clot	1 (x 0.5 mL)	1 (x 0.5 mL)
EDTA-Blood	AHS: 3 mL FOCS: 2 mL	Plasma	~ 6 (x 0.5 mL)	~ 6 (x 0.5 mL)
		Red Blood Cells	1	1
		Granulocytes	2	1
		Mono-nuclear Cells	~ 4 (x 0.5 mL)	~ 4 (x 0.5 mL)
Heparin-Blood	AHS: 2 mL	Plasma	~ 4 (x 0.5 mL)	~ 4 (x 0.5 mL)
		Red Blood Cells	1	1
		Granulocytes	1	1
		Mono-nuclear Cells	~ 4 (x 0.5 mL)	~ 4 (x 0.5 mL)
TOTAL			~ 30	~ 20

Thermo Matrix 2D Barcoded Tube (0.5 mL)

-80°C

Hiroshima

Nagasaki

N₂ Tank

Cryogenic Vial (2 mL)

AHS and FOCS Samples Provided in 2019 – 2020

Health Examinations

- **AHS**: A-bomb Survivors, Biennial
- **FOCS**: Survivors' Offspring, Every 4 Years

Nov 2019 – Oct 2020


City	Subjects			Tubes		
	AHS	FOCS	TOTAL	Blood	Urine	TOTAL
Hiroshima	562	1,388	1,950	37,990	7,667	45,657
Nagasaki	304	663	967	17,186	3,771	20,957
TOTAL	866	2,051	2,917	55,176	11,438	66,614

AHS Samples Stored at BRC

AHS: Adult Health Study

As of Oct 2020

Type	Start Year	Subjects	Tubes	Storage Condition
Serum	1969	16,800	536,000	-80°C, 4°C
Plasma	1990	8,900	298,000	-80°C
Blood Clot/Cells	1990	9,100	155,000	-80°C
			142,000	Liquid N ₂
Urine	1999	7,100	125,000	-80°C
TOTAL			1,256,000	



FOCS Samples Stored at BRC

FOCS: F1 Clinical Study

As of Oct 2020

Type	Start Year	Subjects	Tubes	Storage Condition
Serum	2002	12,600	257,000	−80°C, 4°C
Plasma	2002	12,600	103,000	−80°C
Blood Clot/Cells	2002	12,700	137,000	−80°C
			58,000	Liquid N ₂
Urine	2002	12,500	112,000	−80°C
TOTAL			668,000	

AHS + FOCS

29,600 Subjects

1,923,000 Tubes


Trio Samples

Type		Subjects	Tubes	Storage
Blood Cells	Mono-nuclear Cells	4,100	11,400	Liquid N ₂
	EBV-Transformed B Cells	4,100	43,200	
	Granulocytes	3,100	6,700	-80°C
	Red Blood Cells	1,400	1,400	
	TOTAL	4,100	62,700	
Plasma		4,100	4,300	-80°C


- Including **1,500 Trios** of **F1 Study subjects and both parents** with known doses, accounting for **900 families**
- Collected **since 1985**

Robotic –80°C Freezer

Brooks BioStore II QuadBank



Various Tubes
(1~2 mL)



Total Capacity

3.9M Thermo Matrix 2D
Barcoded Tubes (0.5 mL)

Room for 1.8M Tubes



Archived Samples, 580K Tubes
1969~2015


230K
2015~20

Unoccupied

0 20 40 60 80 100%

DNA Purification from Blood Clots


DNA was extracted from **4,664 blood clots** provided by **2,642 AHS** participants **10–15 years ago**, using an automated DNA extractor, MagCore®.




	DNA (μ g)
Average	7.5
Maximum	39.0
Mode	5.2

Quality Assessment of DNA by Electrophoresis

Integrity of DNA, extracted from **blood clots** preserved at **-80° C** for **10–15 years**, was assessed with **TapeStation**.



DNA Integrity Number (DIN) ≥ 8.1



Laboratory Information Management System (LIMS)

Commercial LIMS was implemented at RERF in 2020

■ To Manage

• Biosample Workflows

- Receipt
- Processing
- Storage
- QA/QC
- Distribution




• Biosample Information


- Inventory
- Quality

■ To Generate Comprehensive Biosample Database

LIMS Composition



Workflow Management by LIMS



Workflow Management by LIMS

Management of Blood Cell Processing

Mono-nuclear Cells

Reagent Name

Lot No.

Reagent Vol.

**Centrifugation
Conditions**

Red Blood Cells

Pathological Tissue Samples

– LSS and Others –

Type	Start Year	Case Number	
		LSS	Others
Autopsy	1948	8,400	4,400
Surgical	1948	12,000	–

Paraffin Blocks



Glass Slides



Future Perspectives

- To establish **policy, rules and procedures** for biosample usage.
- To establish **SOPs for QA/QC** of blood and urine samples.
- To complete **inventory of pathological samples**, *i.e.* indexing, ordering, and recording the samples in a database.

Stakeholder Committee on Usage of RERF's Stored Biosamples

- **Established by the RERF in 2018 to obtain objective opinions to draw up policies for fair use of biosamples.**
- **Consisting of local academic and legal experts, A-bomb survivors, and others.**
- **Formal advice was issued** last month including the following issues ...

Main Issues in Advice from Stakeholder Committee

- Establishment of **trustful relationship with A-bomb survivors** and general public through effective information disclosure
- Adherence to RERF's objectives to study radiation effects **for peaceful purposes, excluding military research**
- Conscientious procedures in obtaining informed consent
- Careful explanation about genome research

Acknowledgements

Biosample Research Center, RERF

Hiroshima

Junko Kajimura, Ph.D.
Tomonori Hayashi, Ph.D.
Yukiko Matsuda, Ph.D.
Keiko Sasaki
Takeshi Kishi
Keiko Furudo
Rie Fukada
Sachiko Muramoto
Mika Yamaoka
Hiroyuki Ryukaku
Namiko Takahashi

Nagasaki

Misa Imaizumi, M.D, Ph.D.
Yoshio Saitsu
Takahiro Suga
Noriko Oka
Yuki Nakayama
Kunio Yamaguchi